this is great news.

Mayo Clinic and Acorda Therapeutics Announce Initiation of Phase 1 Trial of Remyelinating Antibody in People with Multiple Sclerosis
Discovered at Mayo Clinic, rHIgM22 Represents Potential New Approach to MS Treatment

ROCHESTER, Minn. & ARDSLEY, N.Y.--(BUSINESS WIRE)--Mayo Clinic and Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). This is a Phase 1 clinical trial enrolling people with MS to assess the safety and tolerability of rHIgM22. The study also includes several exploratory efficacy measures